Drug Profile
Research programme: 4-1BB receptor agonists - Apogenix
Alternative Names: CD137 agonists - Apogenix; HERA-CD137LLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Apogenix
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action CD137 antigen agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Aug 2023 Discontinued - Preclinical for Solid tumours in Germany (unspecified route) (Apogenix pipeline, August 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Solid-tumours in Germany
- 06 Sep 2017 Preclinical data in Solid tumours presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)